Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 4:32 PM
Ignite Modification Date:
2025-12-25 @ 2:24 PM
NCT ID:
NCT05032066
Pre Assignment Details:
This trial consisted of 2 parts. During part 1 (Core Phase) participants were randomized in 1:1:1 ratio to receive HZN-825 300 mg once daily (QD), twice daily (BID) or placebo, for 52 weeks. Part 2 (Extension Phase) was an optional, open-label extension (OLE) where all participants received HZN-825 BID for 52 weeks. 11 participants who completed part 1 did not enter the part 2.
Recruitment Details:
A total of 153 participants with Idiopathic Pulmonary Fibrosis (IPF) were enrolled in 16 countries between January 2022 and December 2024.
Study:
NCT05032066
Study Brief:
Results Section:
NCT05032066